NYSE · NVS
Healthcare · Drug Manufacturers - General
$143.75
Up+$0.64 (+0.45%)
Updated Oct 10, 2026, 3:22 PM
SID Score
6.0/10
Composite research score
Smart Money
43/100
Neutral
Price performance · NVS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
NVS closed at $143.75 after 21 trading sessions, up 4.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $142.92 | $143.96 | $142.80 | $143.75 | 1.9M |
| Oct 8, 2026 | $142.77 | $143.29 | $140.68 | $143.11 | 1.53M |
| Oct 7, 2026 | $143.12 | $144.275 | $142.545 | $143.28 | 1.85M |
| Oct 6, 2026 | $141.32 | $141.39 | $139.665 | $140.79 | 1.57M |
| Oct 5, 2026 | $141.02 | $141.02 | $139.31 | $140.93 | 1.33M |
| Oct 2, 2026 | $141.46 | $141.57 | $139.95 | $141.00 | 2.25M |
| Oct 1, 2026 | $142.22 | $142.50 | $140.87 | $141.05 | 2.06M |
| Sep 30, 2026 | $145.39 | $145.50 | $142.56 | $142.57 | 3.06M |
| Sep 29, 2026 | $144.81 | $146.18 | $144.46 | $145.71 | 1.6M |
| Sep 28, 2026 | $145.77 | $147.03 | $145.72 | $146.88 | 1.95M |
| Sep 25, 2026 | $144.57 | $145.51 | $144.0003 | $145.46 | 1.17M |
| Sep 24, 2026 | $143.00 | $144.66 | $142.91 | $143.57 | 1.89M |
| Sep 23, 2026 | $143.15 | $143.94 | $142.025 | $142.71 | 2.52M |
| Sep 22, 2026 | $141.26 | $141.80 | $140.00 | $141.28 | 1.54M |
| Sep 21, 2026 | $141.96 | $142.18 | $140.96 | $140.98 | 1.55M |
| Sep 18, 2026 | $140.87 | $141.15 | $139.60 | $140.37 | 2.25M |
| Sep 17, 2026 | $140.12 | $141.21 | $139.97 | $140.92 | 1.71M |
| Sep 16, 2026 | $140.58 | $141.46 | $138.28 | $138.70 | 1.89M |
| Sep 15, 2026 | $138.76 | $139.11 | $137.37 | $138.62 | 2.37M |
| Sep 14, 2026 | $141.64 | $141.64 | $138.99 | $138.99 | 2.48M |
| Sep 11, 2026 | $139.31 | $139.55 | $137.00 | $137.16 | 2.35M |
The latest Smart Investors Daily articles mentioning NVS.
Company
Market Activity
Research & News
NVS research
Company profile and research snapshot.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Sell | — |
| Sep 23, 2026 | LANDESBANK BADEN-WUERTTEMBERG | Hold | — |
| Sep 21, 2026 | BERENBERG | Hold | — |
| Sep 18, 2026 | JEFFERIES | Hold | — |
| Sep 17, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 10, 2026
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Yahoo · Oct 9, 2026
Melexis has delivered a mixed share price record over recent years, which raises a direct question for anyone looking at the stock today. Is the current market valuation really supported by the cash flows the business can generate over time, based on a detailed Discounted Cash Flow (DCF) view? The share price has fallen 17.3% over 5 years, which puts long term cash generation and the durability of Melexis' business model under the microscope for valuation focused investors. The group relies...
Yahoo · Oct 9, 2026
Suominen Corporation’s stock exchange release on October 9, 2026, at 11:00 a.m. (EEST) Suominen Corporation will publish its financial reports in 2027 as follows: March 2, 2027 – Financial Statements Bulletin for 2026Week commencing April 5, no later than April 8, 2027 – Annual Report for 2026, including Financial StatementsApril 27, 2027 – Interim Report for January–March 2027August 6, 2027 – Half-Year Financial Report for January–June 2027November 3, 2027 – Interim Report for January–September
Yahoo · Oct 9, 2026
Investing.com -- Barclays downgraded Ryanair and Norwegian Air Shuttle to Equal Weight from Overweight, saying persistently high fuel prices threaten fourth-quarter and 2027 profits across European airlines.
Interpretive context generated from the platform’s current data sources.
Novartis AG shares currently trade at $143.75, reflecting a 4.1% gain over the past month but a 7.1% decline over the trailing three-month period, per SID market data. On a one-year basis, NVS has returned 8.21%, underperforming the broader market. The stock is currently trading below both its 50-day moving average of $149.29 and its 200-day moving average of $150.75, indicating sustained downward pressure relative to intermediate and longer-term trend lines. The 14-day relative strength index stands at 59.0, positioning NVS in neutral territory and away from overbought or oversold thresholds. According to Massive/Polygon data, average daily trading volume is approximately 1.65 million shares. Novartis carries a beta of 0.438, reflecting significantly lower volatility than the broader market, consistent with the defensive characteristics typical of large-cap healthcare companies. The company's market capitalization stands at approximately $259 billion.
Novartis AG trades at a price-to-earnings ratio of 18.18, according to SID market data, positioning it within a moderate valuation range for the healthcare sector. The company's price-to-book ratio stands at 5.90, suggesting the market assigns a significant premium to Novartis's net asset base, which is common among pharmaceutical companies with substantial intangible assets and intellectual property portfolios. The PEG ratio is negative at approximately -0.79, reflecting a contraction in projected earnings growth and limiting the usefulness of this metric for growth-adjusted valuation comparisons. Per SEC filings, Novartis offers a dividend yield of approximately 3.31%, providing an attractive income component relative to the broader equity market. With a market capitalization of roughly $259 billion, Novartis remains one of the largest pharmaceutical companies globally. Its valuation metrics collectively reflect a mature, income-generating enterprise rather than a high-growth profile within the healthcare industry.
Novartis AG carries an overall smart money score of 43 out of 100, signaling a neutral stance among sophisticated market participants, per SID market data. Institutional activity represents the strongest component, scoring 21.0 out of 25, indicating robust engagement from large asset managers and pension funds consistent with Novartis's status as a mega-cap healthcare holding. Insider activity scores 12.5 out of 25, reflecting moderate but not particularly aggressive buying or selling patterns among company executives, according to SEC Form 4 filings. Dark pool activity registers at 8.5 out of 25, suggesting below-average off-exchange institutional trading interest in recent periods. Congressional trading activity is negligible at 0.8 out of 25, per 13F institutional filings and congressional disclosure records. The divergence between strong institutional engagement and weaker dark pool and congressional scores suggests that while traditional institutional holders maintain their positions, there is limited incremental conviction-driven accumulation from alternative smart money channels at current price levels.
Novartis AG delivered a notable earnings beat in its most recently reported quarter, posting actual earnings per share of $2.41 against a consensus estimate of $2.16, representing a positive surprise of $0.25 or approximately 11.6%, according to company earnings reports. Looking ahead, analyst estimates project sequential earnings growth across upcoming quarters, with estimates of $2.10, $2.13, and $2.24 for the next three reporting periods, per consensus data. The upward trajectory in estimates suggests analysts anticipate steady operational improvement and revenue expansion. The next earnings report is scheduled for approximately May 1, 2026, with a consensus EPS estimate of $2.10. The progression from $2.10 to $2.24 across forward quarters implies an expected improvement of approximately 6.7% over the forecast horizon. Novartis's recent earnings momentum, highlighted by the $0.25 beat, provides a constructive baseline heading into the upcoming reporting cycle.
Recent Wall Street coverage of Novartis AG reveals a predominantly cautious consensus, according to SID consensus data. Among five analyst actions issued between September 17 and September 23, 2026, three firms — Landesbank Baden-Wuerttemberg, Berenberg, and Jefferies — reiterated Hold ratings, representing 60% of the recent coverage. Rothschild & Co Redburn maintained a Sell rating, while Baader Europe/AlphaValue reiterated a Buy recommendation, per Wall Street analyst reports. The distribution of one Buy, three Holds, and one Sell reflects a balanced-to-cautious view among European-focused research houses. Notably, none of the five recent actions represented rating changes, with all firms reaffirming prior positions, suggesting a settled consensus at current valuation levels. The prevalence of Hold ratings aligns with Novartis's current positioning below key moving averages while carrying moderate valuation multiples. The lack of upgrades or downgrades indicates limited catalysts are being priced into near-term analyst models for the stock.
The latest Smart Investors Daily articles mentioning NVS.
